Physician profile
John R Mann
NPI 1639118102
$2,010.12
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $316 · 2021: $160 · 2022: $522 · 2023: $12.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $519.37 | 2021-2022 | |
| Amgen INC. | $332.46 | 2019 | |
| Novo Nordisk INC | $262.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $152.70 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $102.83 | 2019 | |
| Lilly USA, LLC | $96.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.46 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $77.97 | 2019-2020 | |
| Endogastric Solutions, INC | $69.50 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $65.47 | 2019-2020 | |
| Glaxosmithkline, LLC. | $53.75 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.92 | 2022-2023 | |
| Amarin Pharma, INC. | $26.23 | 2019 | |
| Zealand Pharma US, INC. | $24.61 | 2020-2021 | |
| Forte Bio-Pharma LLC | $16.84 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.46 | 2019 | |
| Abbvie INC. | $15.25 | 2019 | |
| Assertio Therapeutics, INC. | $13.83 | 2019 | |
| Allergan, INC. | $12.68 | 2019 | |
| Hikma Pharmaceuticals USA | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.